Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD)

Olsson, Katherine; Gerard, Christopher J.; Zehnder, James L.; Jones, Carol D.; Ramanathan, Rajeev; Reading, Chris; Hanania, Elie G.

doi:10.1038/sj.leu.2401575

Cited by 49 publications

(25 citation statements)

References 21 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30 Perhaps recently introduced molecular methods with real-time PCR may be able to close the diagnostic gap from which PET obviously suffers. 31,32 As a possible limitation to our study, the small number of patients must be mentioned. Therefore, HD and NHL were analyzed together.…”

Section: Leukemiamentioning

confidence: 98%

Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation

et al. 2002

View full text Add to dashboard Cite

We have determined the predictive value of [ 18 F]2-fluoro-2-deoxy-glucose (FDG-PET) in patients with Hodgkin's disease (HD) and aggressive non-Hodgkin's lymphoma (NHL) scheduled for high-dose therapy with stem cell transplantation (HDT/SCT). Inclusion criteria were the presence of an FDG-PET scan after chemotherapy (ChT) within 8 weeks prior to HDT/SCT and available follow-up data. Sixteen patients (10 NHL and six HD) were observed during a follow-up period of 4 to 28 months (median 13 months). Before SCT, five patients had a negative PET, three were weakly positive, two moderately positive, and six strongly positive. None of the five patients with a negative PET before HDT/SCT relapsed and two of three patients with a weakly positive scan are still in remission after HDT/SCT. Of eight patients with a moderate or high positive PET before HDT/SCT, seven relapsed and one died of early HDT/SCT related complications (P Ͻ 0.01). Three of eight relapsing patients died of lymphoma 5 to 10 months after SCT and in one additional patient not responding to HDT/SCT, the main cause of death was chronic toxicity 4 months after transplantation. After 12 months, in PET-negative patients the overall and relapse-free survival was 100%, in PET-positive patients 55% and 18%, respectively. In NHL, two patients with negative PET, but with an age-adjusted international prognostic index (AaIPI) of 2 and one with AaIPI ‫؍‬ 1 are still in remission. In the seven PET-positive subjects, one patient with AaIPI = 0, three with AaIPI ‫؍‬ 1, and two with AaIPI ‫؍‬ 2 relapsed. We conclude that FDG-PET is accurate in the prediction of relapse prior to HDT/SCT in patients with lymphoma. It provides additional information when compared with the AaIPI.

show abstract

Section: Leukemiamentioning

confidence: 98%

Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation

et al. 2002

View full text Add to dashboard Cite

show abstract

“…This strategy has been used to quantify MRD in patients with chronic myelogenous leukemia, 28,29 acute myelogenous leukemia [30][31][32] acute promyelocytic leukemia 33 and lymphoma. 34,35 In ALL, the TAL-1 deletion is present in approximately 5% of total patients and therefore our RQ-PCR assay will simplify the assessment of MRD in those cases.…”

Section: Discussionmentioning

confidence: 99%

Quantification of minimal residual disease in T-lineage acute lymphoblastic leukemia with the TAL-1 deletion using a standardized real-time PCR assay

et al. 2001

View full text Add to dashboard Cite

Hematologic relapse remains the greatest obstacle to the cure of children with acute lymphoblastic leukemia (ALL). Recent studies have shown that patients with increased risk of relapse can be identified by measuring residual leukemic cells, called minimal residual disease (MRD), during clinical remission. Current PCR methods, however, for measuring MRD are cumbersome and time-consuming. To improve and simplify MRD assessment, we developed a real-time quantitative PCR (RQ-PCR) assay for detection of leukemic cells that harbor the TAL-1 deletion. We studied serial dilutions of leukemic DNA and found the assay had a sensitivity of detection of one leukemic cell among 100 000 normal cells. We then investigated 23 samples from eight children with ALL in clinical remission. We quantified residual leukemic cells by using the TAL-1 RQ-PCR assay and by using limiting dilution analysis. In 17 samples, both methods detected MRD levels у0.001%. The percentages of leukemic cells measured by the two methods correlated well (r 2 ‫؍‬ 0.926). In the remaining six samples, both methods detected fewer than 0.001% leukemic cells. We conclude the TAL-1 RQ-PCR assay can be used for rapid, sensitive and accurate assessment of MRD in T-lineage ALL with the TAL-1 deletion. Leukemia (2001) 15, 166-170.

show abstract

“…9,[11][12][13][14] In order to save reagents and costs, we repeated the real-time PCR in 25 l reaction volumes leaving all concentrations unchanged except for DNA (1 g/tube). Neither peak normalized reporter fluorescence intensities nor threshold cycle numbers significantly changed and no loss of sensitivity was observed (Figure 2).…”

Section: Optimization Of the Real-time Pcr Assay Reaction Volumementioning

confidence: 99%

“…9,[11][12][13][14] This technique uses an oligonucleotide hybridization probe in combination with standard amplification primers. The probe positioned internally to the PCR primers is labelled with a reporter fluorescent dye at the 5Ј end and a quenching dye at the 3Ј end.…”

Section: Introductionmentioning

confidence: 99%

Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR

et al. 2000

View full text Add to dashboard Cite

Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD)

Cited by 49 publications

References 21 publications

Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation

Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation

Quantification of minimal residual disease in T-lineage acute lymphoblastic leukemia with the TAL-1 deletion using a standardized real-time PCR assay

Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR

Contact Info

Product

Resources

About